AbbVie Inc. · Healthcare
$263.96
-0.8%
Sep 19, 2026
D
WeakGraded against ABBV's own history at this drawdown — not the market's.
What it means: ABBV's own history does not strongly favor buying at this level yet.
What to do: Consider watching and waiting for a deeper dip or a higher grade.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides
Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.
In plain terms: ABBV is 0.8% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.
AbbVie (ABBV) sits 0.8% off its peak and is currently at or near all-time highs, last printing at $263.96. That puts ABBV in a momentum regime: buyers are in control and there's no meaningful technical damage on the chart yet.
ABBV has rarely been in the 0% to 5% drawdown band over its trading history, so the sample size for forecasting forward returns is small. We surface this transparently — small samples are still informative, but the confidence interval is wider than for assets with decades of data at this level.
S&P 500 names behave differently from small-caps at the same drawdown level — the Dipsern segmentation is per-ticker, so historical base rates for ABBV reflect its own volatility regime, not the market's. At this level the Dipsern signal is mostly tracking momentum, not mean reversion. Most buying-the-dip frameworks aren't relevant when there is no dip.
Five tickers closest to ABBV's distance from all-time high. Same category, one tap away.
We segment 40+ years of ABBV's price history into 20 equal-width drawdown bands and compute forward median returns, win rates, and prediction error per band. No look-ahead bias. Pure NumPy. Open math, gated numbers.
Years of history
40+
Drawdown bands
20
Look-ahead bias
None
Data sources
4
See the Dipsern grade, median returns, win rates, prediction accuracy, 8 interactive charts, historical price paths, and a plain-English verdict for ABBV.
Dipsern is research and a second opinion — not a broker. You'd buy ABBV at your own broker.
Analyze ABBV FreeNo credit card required · 5 free analyses per month
Signal computed Sep 19, 2026 using default parameters (90-day return period, 20 segments, 0.95 decay). Data sourced from Yahoo Finance, Binance, CoinGecko, and Steam Market.